Essential drugs; price increases; limits
HB 2757 would create a new chapter in Title 36 governing prescription drug pricing, focused on “essential off-patent or generic drugs.” The bill defines those drugs as certain essential medicines with expired exclusivity and limited market competition, and it prohibits manufacturers and wholesale distributors from engaging in “price gouging,” defined as an unconscionable increase in price. The bill is aimed at drugs that are widely considered medically important but have few manufacturers, making them vulnerable to sharp price increases.
The bill sets a trigger for state action when a drug’s price rises by at least 50 percent in a year and the drug exceeds an $80 threshold for a 30-day supply, full course of treatment, or comparable quantity. When those conditions are met, the Arizona Health Care Cost Containment System may notify the attorney general, who can demand cost and pricing information from manufacturers and distributors, seek records, and petition a court for injunctive relief, restitution, a requirement to supply the drug to AHCCCS at the prior price for up to one year, and civil penalties of up to $10,000 per violation. The bill also requires an opportunity for the manufacturer or distributor to meet with the attorney general before certain remedies are pursued, and it treats submitted business information as confidential commercial information.
If enacted, HB 2757 would add a new enforcement framework to Arizona law for prescription drug pricing and would expand the attorney general’s authority over certain drug price increases. It would directly affect manufacturers and wholesale distributors of qualifying generic or off-patent drugs, as well as consumers, third-party payors, and the state medical assistance program, particularly AHCCCS. The bill also creates statutory definitions that could be used in future enforcement or litigation involving drug pricing and market competition.
Because no committee transcripts or votes are provided, there is no recorded legislative debate or voting history to gauge sentiment. Based on the bill text alone, the measure appears to reflect a consumer-protection and affordability approach to prescription drug pricing, with a focus on preventing sharp increases in the cost of essential medicines. The absence of recorded opposition or amendments in the provided materials means any contention can only be inferred from the structure of the bill rather than from documented discussion.
The main likely points of contention are the breadth of the price-gouging standard, the $80 and 50 percent triggers, the attorney general’s investigatory and enforcement powers, and the potential burden on manufacturers and distributors to disclose pricing and cost information. Another possible issue is whether the bill could affect drug availability or pricing decisions in a market with limited competition, especially because it targets drugs with three or fewer manufacturers and allows courts to order continued supply to AHCCCS at a prior price.
HB 2757 would add Chapter 42 to Title 36 of the Arizona Revised Statutes and create a new state regulatory and enforcement scheme for prescription drug pricing. It would prohibit price gouging on qualifying essential off-patent or generic drugs, authorize AHCCCS to flag large price increases to the attorney general, and empower the attorney general and courts to compel disclosures, enjoin violations, order restitution, impose civil penalties, and require temporary continued supply to the state medical assistance program at the pre-violation price.
No committee discussion or vote history is provided, so there is no documented legislative sentiment in the record supplied. From the bill text, the measure appears to be motivated by concern over drug affordability and access, especially for essential medicines with limited competition. The overall tone is consumer-protective and enforcement-oriented, suggesting support from lawmakers concerned about prescription drug costs, though the lack of recorded debate means opposition or support cannot be confirmed from the provided materials.
The most likely areas of contention are the bill’s definition of “unconscionable increase,” the 50 percent annual price-increase trigger, and the $80 threshold used to identify potentially problematic price hikes. Manufacturers and wholesale distributors may object to the reporting demands, confidentiality provisions, and the attorney general’s authority to seek records, injunctions, restitution, and civil penalties. Another likely point of dispute is whether the bill could interfere with pricing flexibility or supply decisions for low-competition generic drugs, while supporters would likely argue that those same market conditions justify stronger state oversight.